Recerca

Àrea 3

Oncologia Hepática

Factor d'impacte: mitjana: 11.72, total: 386.75

Articles de l'any 2008
Original
  • Focal gains of VEGFA and molecular classification of hepatocellular carcinoma

    Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, Leblanc AC, Donovan DJ, Thung SN, Sole M, Tovar V, Alsinet C, Ramos AH, Barretina J, Roayaie S, Schwartz M, Waxman S, Bruix J, Mazzaferro V, Ligon AH, Najfeld V, Friedman SL, Sellers WR, Meyerson M, Llovet JM
    CANCER RES. 2008; 68: 6779-6788. IF: 7.672

  • Liver transplantation for hepatocellular carcinoma: Extension of indications based on molecular markers

    Schwartz M, Dvorchik I, Roayaie S, Fiel MI, Finkelstein S, Marsh JW, Martignetti JA, Llovet JM
    J HEPATOL. 2008; 49: 581-588. IF: 6.642

  • Noninvasive prediction of clinically significant portal hypertension and esophageal varices in patients with compensated liver cirrhosis

    Berzigotti A, Gilabert R, Abraldes JG, Nicolau C, Bru C, Bosch J, Garcia-Pagan JC
    AM J GASTROENTEROL. 2008; 103: 1159-1167. IF: 6.101

  • Sorafenib in advanced hepatocellular carcinoma

    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, DeOliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J
    NEW ENGL J MED. 2008; 359: 378-390. IF: 52.589

  • Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma

    Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR
    NEW ENGL J MED. 2008; 359: 1995-2004. IF: 52.589

  • Dark-lumen MR colonography with fecal tagging: a comparison of water enema and air methods of colonic distension for detecting colonic neoplasms

    Rodriguez S, Pages M, Castells A, DeJuan C, Bordas JM, Rimola J, Ayuso JR, Ayuso C
    EUR RADIOL. 2008; 18: 1396-1405. IF: 3.405

  • Optimization of liver grafts in liver retransplantation: A European single-center experience

    Marti J, Charco R, Ferrer J, Calatayud D, Rimola A, Navasa M, Fondevila C, Fuster J, Garcia-Valdecasas JC
    SURGERY. 2008; 144: 762-769. IF: 3.004

  • Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma

    Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, VanLaarhoven S, Fiel MI, DiFeo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, Llovet JM
    GASTROENTEROLOGY. 2008; 135: 1972-1983. IF: 11.673

  • Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma

    Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, Hod E, Villanueva A, Loke J, Tarocchi M, Akita K, Shirasawa S, Sasazuki T, Martignetti JA, Llovet JM, Friedman SL
    GASTROENTEROLOGY. 2008; 134: 1521-1531. IF: 11.673

  • Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma

    Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, Boix L, Sala M, Varela M, Llovet JM, Bru C, Bruix J
    HEPATOLOGY. 2008; 47: 97-104. IF: 10.734

  • Magnetic resonance enterography in Crohn's disease: a new diagnostic tool?

    Rimola J, Rodriguez S, Ayuso C
    MED CLIN-BARCELONA. 2008; 130: 580-584. IF: 1.337

Revisió
  • Experimental models of hepatocellular carcinoma

    Newell P, Villanueva A, Friedman SL, Koike K, Llovet JM
    J HEPATOL. 2008; 48: 858-879. IF: 6.642

  • Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

    Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M
    MOL CANCER THER. 2008; 7: 3129-3140. IF: 4.8

  • Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps

    Villanueva A, Toffanin S, Llovet JM
    CURR OPIN ONCOL. 2008; 20: 444-453. IF: 3.692

  • Design and endpoints of clinical trials in hepatocellular carcinoma

    Llovet JM, DiBisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ
    J NATL CANCER I. 2008; 100: 698-711. IF: 15.678

  • Molecular targeted therapies in hepatocellular carcinoma

    Llovet JM, Bruix J
    HEPATOLOGY. 2008; 48: 1312-1327. IF: 10.734

Editorials
  • Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials

    Newell P, Villanueva A, Llovet JM
    J HEPATOL. 2008; 49: 1-5. IF: 6.642

  • Hepatitis B virus genotype and mutants: Risk factors for hepatocellular carcinoma

    Llovet JM, Lok A
    J NATL CANCER I. 2008; 100: 1121-1123. IF: 15.678

  • Locoregional treatment for hepatocellular carcinoma: From clinical exploration to robust clinical data, changing standards of care

    Forner A, Bruix J
    HEPATOLOGY. 2008; 47: 5-7. IF: 10.734

  • Liver cancer: An evolving challenge reaching research maturity

    Bruix J
    HEPATOLOGY. 2008; 47: 1103-1104. IF: 10.734

Tornar